Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Rare disease

Eosinophilic granulomatosis with polyangiitis

  • 7 clinical trials
Quick filters

7 Clinical trials

Hypereosinophilic syndrome+1

Recruiting

Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Eosinophilic granulomatosis with polyangiitis

Recruiting

Study on the Effects of Mepolizumab on Nasal Health and Immune Response in Patients with Eosinophilic Granulomatosis with Polyangiitis (eGPA)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mepolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Eosinophilic granulomatosis with polyangiitis

Recruiting

Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
  • Sponsor:Ns Pharma Inc.

Eosinophilic granulomatosis with polyangiitis

Not yet recruiting

Study on the Effectiveness of Tezepelumab for Adults with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Imperial College London Limited

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on Mepolizumab and Drug Combination for Patients with Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB
See all trials →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.